Apollomics (NASDAQ:APLM) Trading 26.9% Higher – Should You Buy?

Apollomics Inc. (NASDAQ:APLM) traded up 26.9% during mid-day trading on Thursday . The stock traded as high as $25.00 and last traded at $20.96. 109,021 shares changed hands during mid-day trading, an increase of 185% from the average session volume of 38,309 shares. The stock had previously closed at $16.52.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Apollomics in a report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Apollomics presently has an average rating of “Sell”.

Apollomics Price Performance

The business’s 50-day moving average price is $17.41 and its 200 day moving average price is $9.97.

Apollomics Company Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.